In this article, we will be taking a look at the 7 Most Promising Gene Editing Stocks According to Analysts.
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells. Once confined largely to research labs, the field has entered a clinical and commercial phase, led by CRISPR-Cas systems. A major milestone was reached in December 2023, when the U.S. Food and Drug Administration approved Casgevy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. This was followed by regulatory clearances across Europe and other regions through 2024 and 2025.
Market growth has accelerated in tandem with these regulatory wins. According to Precedence Research, the global gene-editing market was valued at approximately $9.30 billion in 2024 and is estimated to reach $10.77 billion in 2025. Long-term forecasts point to a market approaching $40 billion by 2034, implying a sustained compound annual growth rate of about 15.7% between 2025 and 2034. The U.S. market mirrors this trajectory, with genome-editing revenues rising from $5.25 billion in 2024 to a projected $24.81 billion by 2034, reflecting a CAGR of 16.8%.
Beyond first-generation therapies, next-wave programs are advancing quickly. Oncology, in vivo liver and cardiovascular applications, and base-editing approaches are moving deeper into clinical development. In early 2024, Beam Therapeutics dosed its first U.S. patient in a base-editing sickle cell trial, while Intellia’s CRISPR programs for transthyretin amyloidosis advanced toward phase 3.
Looking ahead, the sector is expected to sustain mid-teens growth through 2034 as late-stage trials expand, regulatory frameworks mature, and enabling technologies, from advanced delivery systems to AI-driven design, scale across U.S. biotech and academic labs.
Our Methodology
For our methodology, we first analyzed several gene-editing-focused ETFs, including the ARK Genomic Revolution ETF, focusing on companies actively engaged in developing and commercializing gene‑editing technologies. From this analysis, we selected stocks with strong upside potential and ranked them in ascending order based on their PT upside as of December 17.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Here is our list of the 11 most promising gene editing stocks according to analysts.
7. 10x Genomics, Inc. (NASDAQ:TXG)
Price Target Upside: 6.25%
10x Genomics, Inc. (NASDAQ:TXG) is one of the eight stocks on our list of most promising stocks.
On December 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight rating, reflecting confidence in the company’s positioning in life sciences tools and expectations of stabilizing end‑market demand. Barclays cited improving conditions for research funding and the tools sector as part of its positive outlook.
In contrast, on December 11, 2025, Citigroup downgraded 10x Genomics, Inc. (NASDAQ:TXG) from Buy to Neutral with an $18 price target, highlighting uncertainty about capital expenditures in academic and biopharma research that could weigh on instrument sales recovery.
These differing assessments are grounded in the recent operational context. For the full‑year 2024, 10x Genomics, Inc. (NASDAQ:TXG) reported revenue of approximately $610.8 million, a slight year‑over‑year decline, reflecting soft demand in some core research segments. Analyst caution also stems from guidance for 2025 that implies modest growth, with revenue expected to be roughly flat given continued funding uncertainty in key markets.
10x Genomics, Inc. (NASDAQ:TXG) is a biotechnology company that develops advanced tools for high‑resolution genomic analysis, especially single‑cell and spatial biology technologies. It is not a traditional gene‑editing therapeutic developer (e.g., it does not create CRISPR‑based drugs), but its platforms are widely used to analyze the effects of gene editing in cells and tissues.
6. Twist Biosciences Corporation (NASDAQ:TWST)
Price Target Upside: 9.65%
Twist Biosciences Corporation (NASDAQ:TWST) is one of the most promising stocks on our list.
TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, reflecting confidence in the company’s margin progress and anticipated performance in the life sciences tools sector.
This follows an Overweight initiation on November 3, 2025, by Stephens with a $41 price target, citing Twist Bioscience (NASDAQ: TWST)’s proprietary silicon‑based DNA synthesis platform as a competitive advantage in synthetic biology and research markets.
Strategic product launches have reinforced investor interest. On December 4, 2025, TWST introduced research‑grade Plasmid DNA Preps designed to support pre‑clinical nucleic acid therapeutics research with animal origin‑free and transfection‑grade options, positioning the company as a more integral supplier for biotech and pharmaceutical discovery workflows.
Twist Bioscience (NASDAQ: TWST) is a biotechnology company that has developed a proprietary silicon‑based DNA synthesis platform to “write” DNA, a core enabling technology for modern genetic research and engineering.
5. Natera, Inc. (NASDAQ:NTRA)
Price Target Upside: 11.24%
Natera, Inc. (NASDAQ:NTRA) stands sixth on our list among the most promising stocks.
TheFly reported on December 15 that J.P. Morgan raised its price target on NTRA from $250 to $260 while maintaining an Overweight rating, reflecting confidence in the company’s growth prospects driven by strong operational momentum and rapid adoption of its Signatera molecular residual disease (MRD) test.
Around the same time, Barclays maintained its Overweight rating with a $270 price target, and Jefferies raised its target to $275, underscoring broad analyst optimism about Signatera’s role in oncology diagnostics and recurring revenue potential.
The bullish sentiment is supported by recent clinical and scientific validation of Signatera. On December 18, Natera, Inc. (NASDAQ:NTRA) announced the publication of Phase III CALGB (Alliance)/SWOG 80702 data in JAMA Oncology showing that Signatera‑positive colorectal cancer patients had significantly improved outcomes when treated with celecoxib plus chemotherapy versus chemotherapy alone, reinforcing the test’s prognostic utility in solid tumors.
Further strengthening confidence, NTRA completed its acquisition of Foresight Diagnostics on December 5, integrating Foresight’s ultrasensitive phased variant MRD technology into the business’s portfolio to enhance ctDNA detection capabilities, especially in lymphoma and other solid tumors. The deal was valued at $275 million upfront with up to $175 million in milestone payments, positioning NTRA to extend its MRD leadership.
Natera, Inc. (NASDAQ:NTRA) is a leader in clinical genetic testing and molecular diagnostics that uses advanced DNA analysis to inform patient care. It enables precision health decisions through interpreting genetic information.
4. Guardant Health, Inc. (NASDAQ:GH)
Price Target Upside: 21.01%
Guardant Health, Inc. (NASDAQ:GH) is one of the most promising stocks.
TheFly reported on December 17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the price target to $120 from $100, reflecting growing confidence in the company’s positioning in cancer diagnostics and growth prospects.
This followed a strong series of price target increases on December 15, including JPMorgan raising its target to $120 from $90 (Overweight), Barclays to $120 from $85 (Overweight), Wells Fargo to $120 from $93 (Overweight), and Leerink Partners to $155 from $115 (Outperform), all underscoring broad analyst optimism.
The bullish sentiment is supported by recent operational progress. On December 11, Guardant Health, Inc. (NASDAQ:GH) announced a strategic collaboration with Trial Library to leverage its genomic testing data and AI‑powered platform to enhance patient identification and access to oncology clinical trials, particularly in underserved communities, strengthening its Biopharma & Data segment alongside its screening business.
GH’s Shield blood‑based colorectal cancer (CRC) screening test continues to demonstrate strong real‑world adoption, with studies showing high patient adherence rates in clinical practice, reinforcing its market potential as an FDA‑approved primary CRC screening option.
Guardant Health, Inc. (NASDAQ:GH) is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary blood tests, vast data sets, and advanced analytics.
3. Tempus AI, Inc. (NASDAQ:TEM)
Price Target Upside: 42.26%
Tempus AI, Inc. (NASDAQ:TEM) stands fourth on our list among the most promising stocks.
TheFly reported on December 15 that BofA Securities analyst Michael Ryskin lowered his price target on TEM to $80 from $90 while maintaining a Neutral rating, reflecting valuation considerations after the rally.
On the same day, JPMorgan analyst Casey Woodring also reduced his price target to $80 from $85, reiterating a Neutral outlook as he assessed the company’s growth prospects against its current share price.
These target revisions came despite continued operational momentum at TEM. The company announced that ten scientific abstracts were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, which took place from December 9 to December 12, 2025. The abstracts highlighted research utilizing the company’s multimodal data platform to support cancer research and clinical insights, underscoring the business’s expanding role in precision medicine.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that applies artificial intelligence (AI) to precision medicine, focusing on genomic sequencing, diagnostic testing, and data analysis to help physicians personalize treatment decisions, especially in oncology.
2. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Price Target Upside: 47.51%
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stands third among the most promising stocks.
TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion, paying $14.50 per share. The deal strengthens BMRN’s position in rare metabolic diseases by adding Amicus’s two marketed therapies: Galafold for Fabry disease and the Pombiliti + Opfolda regimen for Pompe disease, which generated about $599 million in combined revenues over the past four quarters.
The corporation expects the transaction to close in Q2 2026, be accretive to non‑GAAP earnings per share within 12 months, and substantially accretive beginning in 2027. It also gains U.S. rights to DMX‑200, a Phase 3 candidate for focal segmental glomerulosclerosis.
Analysts largely praised the strategic fit. Leerink Partners, Oppenheimer, and Needham highlighted the deal’s synergy with BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN)’s global infrastructure and enzyme therapy focus, and its potential to boost sales and long‑term growth. Consensus remains positive (“Moderate Buy”) with an average price target near ~$88, implying significant upside, though earlier ratings had included Holds or downgrades based on competitive pressures and pricing concerns prior to the deal.
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) is a genetics‑centric biotech leader that broadly aims to turn genetic discoveries into therapies. Its primary engagement with gene‑based technologies focuses on gene therapy, especially viral vector‑mediated delivery of functional genes for rare genetic diseases.
1. Wave Life Sciences Ltd. (NASDAQ:WVE)
Price Target Upside: 99.49%
Wave Life Sciences Ltd. (NASDAQ:WVE) tops our list for being one of the most promising stocks.
TheFly reported on December 16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an Outperform rating, citing highly encouraging interim Phase 1 data for WVE‑007, an investigational siRNA therapy that showed meaningful reductions in visceral and total body fat alongside lean mass increases in the INLIGHT trial.
Truist Financial followed on December 15, boosting its price target to $50 from $36 and reaffirming a Buy rating, highlighting clinical durability and safety as key valuation drivers.
Wave Life Sciences Ltd. (NASDAQ:WVE) ’s December 8 Phase 1 INLIGHT results for WVE‑007 demonstrated a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat at three months after a single 240 mg dose, along with increased lean mass, differentiating it from many existing obesity therapies and supporting the broader opportunity in metabolic diseases.
Financially, WVE strengthened its balance sheet via an upsized ~$402.5 million public offering priced at $19 per share on December 9, providing runway into late 2028 to advance WVE‑007 and other RNA programs.
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical‑stage genetic medicines company developing RNA‑targeting therapeutics for genetically defined diseases. Its proprietary PRISM platform designs stereopure oligonucleotides for RNA editing, splicing, RNA interference (RNAi), and antisense silencing to precisely modulate gene expression and protein production.
While we acknowledge the potential of WVE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WVE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. 7 Most Promising Gene Editing Stocks According to Analysts is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
